Topical Imiquimod Treatment of Lentigo Maligna

• Author(s): Ventura, F ; Rocha, J ; Fernandes, JC ; Pardal, F ; Brito, C
• Date: 2009
• Persistent ID: http://hdl.handle.net/10400.23/149
• Origin: Repositório Científico do Hospital de Braga
• Subject(s): Neoplasias da Pele; Lentigo; Imiquimod
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório Científico do Hospital de Braga

Description

Lentigo maligna (LM) is the in situ phase of lentigo maligna melanoma, which may progress to invasive melanoma if left untreated. It mainly occurs on sun-exposed areas of elderly patients. The lesions can be large and conventional surgery can be difficult, particularly on the face. Recent reports indicate that topical imiquimod 5% cream is effective in the treatment of LM. It may be an alternative when surgery or other classical treatments are not possible in elderly patients. We describe an 80-year-old Caucasian woman with a 10-year history of a histologically verified extensive LM of the face. She was treated with imiquimod 5% cream once daily. After four months it showed complete clinical response. One year after the treatment the patient was still free from recurrence.